Profile Picture
Robert “Skip” Cummins
Skip is a proven visionary and pioneer of new technologies, new products, new markets and new business models to create significant shareholder value.

At A Glance

  • CEO, Chairman, Board Member
  • Board of Director experience as a board member, Chairman of the Board and member of Audit and Compensation Committees in privately held and publicly traded companies in a variety of industries
  • High growth venture capital backed and publicly traded medical device companies
  • Recruited high value added board members
  • Formulated long-term fund raising and shareholder liquidity plans
  • Implemented Sarbanes-Oxley compliant governance policies
  • Venture Capital and Commercial Banking Experience

Key Leadership Accomplishments

  • Raised over $250 million of private and public equity and debt capital
  • Achieved 10 year compound annual sales growth in a public company of 55% from $1.5 million to $121 million
  • Achieved 10 year compound annual growth in public shareholder value of 35%
  • Raised $500 million of capital from institutional limited partners

Bio

Robert P. “Skip” Cummins is a proven visionary and pioneer of new technologies, new products, new markets and new business models to create significant shareholder value. He has approximately 15 years of experience as one of four general partners in The Vista Group, a venture capital partnership that raised over $700 million in capital, invested private debt and equity capital in companies at all stages of development from seed capital to start-up to profitable growth in a variety of industries including hardware and software, medical devices, healthcare services, biotechnology etc., and generated an average compound annual rate of return exceeding 20 percent for its limited partners. Skip also has over 15 years of experience as CEO of medical device companies including Cyberonics, Inc., during which time he raised over $250 million of private and public debt and equity capital and pioneered new patents, new products, new FDA approvals, new coverage, coding and reimbursement and new sales and marketing models to grow sales at a compound annual rate of 55 percent and increase public shareholder value at a compound annual rate of 36 percent during his 11-year tenure as Chairman and CEO.